OutSystems Raises $360 Million Investment from KKR and Goldman Sachs to Solidify Its Leadership Position in the Fast-Growing Low-Code Application Development Market
OutSystems, the global leader in low-code rapid application development, today announced it has raised $360 million in an investment round from KKR and Goldman Sachs. The funding values the company at well over $1 billion, and the proceeds will be used to accelerate business expansion and for R&D in new advancements in software automation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180605005431/en/
OutSystems Raises $360 Million in an Investment from KKR and Goldman Sachs (Photo: Business Wire)
The OutSystems low-code platform enables customers to achieve significant efficiency gains in building and supporting enterprise-grade applications. By leveraging automation, artificial intelligence, and deep technology integrations, software developers and business users can build applications through an intuitive, visual interface, rather than traditional coding. Customers experience strong cost savings and create competitive advantages by developing custom applications in days and weeks versus months and years, despite a shortage of skilled developers.
Companies such as Toyota, Logitech, Deloitte, Ricoh, Schneider Electric, and GM Financial use the OutSystems low-code platform to rapidly develop custom applications that digitalize and differentiate their business. The platform can support a wide range of enterprise applications: from large, mission-critical solutions that replace aging legacy ERP/CRM systems, to mobile and web apps for internal processes, to customer experiences like online banking, account enrollment, and customer self-service.
OutSystems is widely regarded as the leader in its market due to the breadth and depth of the platform. The company serves thousands of customers globally and is recognized as one of the fastest-growing technology companies with revenues well above $100 million and growing at more than 70 percent annually.
“We’re attacking one of the biggest problems facing businesses today -- the lack of speed and agility of traditional software development that is hindering digital transformation initiatives around the world,” said Paulo Rosado, OutSystems CEO. “We see companies struggle with this every day and we’re thrilled to be partnering with KKR and Goldman Sachs to solve this problem by bringing more innovation to our customers and re-defining the future of enterprise software development.”
“We believe we are in the early innings of what will be an extended period of significant growth in the low-code application development market, and we are very excited to be backing a category leader like OutSystems,” said Stephen Shanley, Director at KKR. Lucian Schoenefelder, Member at KKR, added: “OutSystems is a perfect fit with KKR’s strategy of supporting best-in-class technology entrepreneurs in their ambition to build global category leaders in large markets. We are very excited to partner with Paulo and his team and will make KKR’s global platform available to support the OutSystems expansion plans.”
“We found that we could point to every major industry sector and find excited and loyal OutSystems customers who have developed unique solutions and are adopting the platform across their organization,” said Kirk Lepke, Vice President at Goldman Sachs Private Capital Investing. Christian Resch, Managing Director at Goldman Sachs Private Capital Investing, added: “OutSystems is directly in line with what we seek for new investments: Support of exceptional founders and management teams in innovative businesses that offer a significant opportunity to create long-term value. We are very much looking forward to backing Paulo and the team to further expand this unique business.”
“The market potential we see with OutSystems is incredible,” said Mike Pehl, OutSystems board member and Managing Partner at Guidepost Growth Equity. “With customers in over 50 countries and nearly 250 partner integrators developing on the platform, it’s clear the low-code market has reached a tipping point, and OutSystems is the clear leader.”
“Founded in 2001, OutSystems has always had a strong vision for their platform and a strong company culture that promotes quality and transparency,” said Joaquim Sérvulo Rodrigues, OutSystems Board Member and Partner at Armilar Venture Partners. “Today, their technology is very advanced, creating a high barrier to entry for potential competitors. OutSystems has created a whole new market.”
“This funding comes on the heels of a record-breaking year for the company,” said Rosado. “OutSystems stands strong as the pioneer in low-code development. Having global investors the caliber of KKR and Goldman Sachs that share our vision for the future of revolutionizing software development sets us on a path of tremendous growth and innovation that will fundamentally change how organizations build software.”
KKR's investment was made through its Next Generation Technology Growth Fund.
Thousands of customers worldwide trust OutSystems, the number one low-code platform for rapid application development. Engineers with an obsessive attention to detail crafted every aspect of the OutSystems platform to help organizations build enterprise-grade apps and transform their business faster. OutSystems is the only solution that combines the power of low-code development with advanced mobile capabilities, enabling visual development of entire applications that easily integrate with existing systems. Explore careers at OutSystems, named a Top Cloud Employer by Forbes three years in a row. Visit us at www.outsystems.com, or follow us on Twitter @OutSystems or LinkedIn.
KKR is a leading global investment firm that manages multiple alternative asset classes, including private equity, growth equity, energy, infrastructure, real estate and credit, with strategic manager partnerships that manage hedge funds. KKR aims to generate attractive investment returns for its fund investors by following a patient and disciplined investment approach, employing world-class people, and driving growth and value creation with KKR portfolio companies. KKR invests its own capital alongside the capital it manages for fund investors and provides financing solutions and investment opportunities through its capital markets business. References to KKR’s investments may include the activities of its sponsored funds. For additional information about KKR & Co. L.P. (NYSE: KKR), please visit KKR’s website at www.kkr.com and on Twitter @KKR_Co.
About Goldman Sachs Private Capital Investing
Goldman Sachs Private Capital Investing ("PCI") is Goldman Sachs' investment platform dedicated to providing long term capital to growth and middle-market companies throughout the US, Europe and Israel. The Goldman Sachs Group, Inc. is a leading global investment banking, securities and investment management firm that provides a wide range of financial services to a substantial and diversified client base that includes corporations, financial institutions, governments and individuals. Founded in 1869, the firm is headquartered in New York and maintains offices in all major financial centers around the world.
About Guidepost Growth Equity
Guidepost Growth Equity is a leading growth equity firm that partners with technology companies offering innovative solutions in large, dynamic markets including tech-enabled services, communications and infrastructure, and data and information services. Prior investments include Dyn (sold to Oracle), Jive Communications (sold to LogMeIn), ProtoLabs (IPO on NYSE), and WP Engine. Guidepost Growth Equity provides the flexible capital, operational support and strategic guidance necessary to support the continued success of growth-stage businesses.
About Armilar Venture Partners
Armilar Venture Partners manages more than 200 million euros of assets. Their worldwide companies provide innovative products and services that are improving our world, the way we live, and the way we do business. Since 2000, Armilar invested in more than 40 seed and early-stage companies and currently has four investment funds, each managed with a hands-on approach.
Ann Conrad, +1 404-512-2518
Alastair Elwen, +44 207 251 3801
Joseph Stein, +44 0207 774 1000
Katelyn Campbell (US), +1 617-502-4300
Laura Rijks (Netherlands), +31 (0)35-5822730
Catia Gil (Portugal), +351 213 026 150
Paula Elliott (UK), +44 (0) 1189 497736
Melinda Ilagan (Singapore), +65 6303 0567
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Personalis, Inc. to Present at Advances in Immuno-Oncology Congress UK 201920.5.2019 10:05:00 EEST | Tiedote
Personalis, Inc., a leader in advanced genomics for cancer, today announced that the company will present at Advances in Immuno-Oncology Congress UK 2019 in London on May 21st at 11:00 AM BST. The presentation, entitled “Advancing Precision Oncology Biomarker Discovery with a Multi-dimensional Immunogenomics Platform,” will introduce Personalis’ new universal cancer immunogenomics platform, ImmunoID NeXT™. In addition to an overview, the presentation will introduce preliminary data from an ongoing study in which this platform is being used to evaluate IO-related biomarkers and potential tumor escape mechanisms in a cohort of melanoma patients treated with anti-PD-1 therapy. ImmunoID NeXT™ is the first platform to provide comprehensive analysis of both a tumor and its immune microenvironment from a single sample. The platform can be used to investigate the key tumor- and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one. This maximizes the
New Study Evaluates Ability of Masimo SpHb® (Noninvasive Hemoglobin) to Estimate Timing for Invasive Measurement to Detect Anemia During Surgery20.5.2019 10:00:00 EEST | Tiedote
Masimo (NASDAQ: MASI) announced today the results of a study published in BMC Anesthesiology in which clinicians at Peking Union Medical College in Beijing evaluated the ability of noninvasive and continuous hemoglobin monitoring with Masimo SpHb® to help clincians estimate when to conduct invasive hemoglobin measurement to detect possible anemia in patients undergoing spine or cytoreductive surgery.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190520005244/en/ Masimo Radical-7® with SpHb® (Photo: Business Wire) Noting that because of the “invasive, time-consuming and intermittent” nature of invasive blood sampling, clincians often forgo these “objective indications” when making transfusion decisions during surgery, Dr. Tang and colleagues sought to determine whether noninvasive, continuous hemoglobin monitoring could aid clinicians in estimating when it might be appropriate to perform an invasive measurement. They enroll
Cleo to Showcase End-to-End Approach to Ecosystem Integration at Gartner AADI in London20.5.2019 10:00:00 EEST | Tiedote
Gartner’s Application Architecture, Development & Integration (AADI) Summit returns to London to provide strategies for solving the pervasive challenges of orchestrating workflows between external B2B and application ecosystems with internal business systems. Cleo, the global leader in ecosystem integration solutions, will be exhibiting in Booth S3 to demonstrate how successful organisations leverage its “outside-in” approach to create seamless end-to-end workflows and help optimize business processes. The Gartner AADI 2019 event, taking place 20-21 May at Park Plaza Westminster, is designed to empower IT and business professionals in transforming their application architecture, agile development, and integration strategies. The event’s focus on application strategies and data processes in the era of the cloud highlights the need for better ways to execute application integration, an inescapable challenge in today’s business landscape. According to the 2019 State of Ecosystem and Integ
Commerzbank Partners with GTC to Further Digitize and Automate its Trade Finance Business20.5.2019 07:00:00 EEST | Tiedote
Commerzbank has entered into a strategic partnership with GlobalTrade Corporation (GTC), a leading Canadian application services provider of innovative multi-bank trade finance solutions. The bank plans to utilise GTC’s @GlobalTrade™ platform to strengthen its digital trade finance product range. As one of Europe’s leading trade finance banks, Commerzbank holds the digitalisation and automation of processes as key priorities. This partnership leverages Commerzbank’s unique network footprint and GTC’s multi-bank technology, coupled with SWIFT connectivity, to meet the trade finance needs of corporate clients across the globe more efficiently and effectively. “We are very pleased to have found a strategic and reliable business partner in the trade finance business in GTC. Together we will provide digital, multi-bank trade finance solutions to our clients as well as an expanded range of trade products,” said Klaus Josef Müller, Head of Trade Finance and Cash Management Product Management
New Exploratory Data from VARSITY, First Head-to-Head Ulcerative Colitis Biologic Study Which Demonstrated Superiority of Vedolizumab to Adalimumab in Clinical Remission at Week 52, Presented at 2019 Digestive Disease Week®20.5.2019 03:16:00 EEST | Tiedote
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced further results from the Phase 3b head-to-head VARSITY study, which demonstrated that the gut-selective biologic vedolizumab (Entyvio®) was superior to the anti-tumor necrosis factor-alpha (anti-TNFα) biologic adalimumab (Humira®) in achieving clinical remission* at week 52 in patients with moderately to severely active ulcerative colitis (UC).1 New exploratory data showed that a greater proportion of patients receiving vedolizumab intravenous (IV) achieved clinical response** at week 14 compared to those treated with adalimumab subcutaneous (SC), 67.1% vs. 45.9% respectively. A separation between the treatment groups was seen as early as week 6, favoring vedolizumab. These results were announced in a Distinguished Abstract Plenary Lecture Presentation at the 2019 Digestive Disease Week® (DDW) annual scientific meeting (May 18-21 in San Diego, CA), one of 18 Takeda sponsored vedolizumab abstracts accep
Age, Gender, Disease Severity Impact Adherence to Long-Term PAP Therapy More Than Previously Thought19.5.2019 22:15:00 EEST | Tiedote
ResMed (NYSE: RMD, ASX: RMD) today revealed several demographic and clinical factors affect adherence to PAP (positive airway pressure) therapy, according to a study it presented at the American Thoracic Society's ATS 2019 International Conference. The study found significant differences in one-year adherence between people of different ages and disease severity levels: Men with sleep apnea are 8.5 percentage points more likely to stay adherent on PAP therapy than women. People over age 60 were 7.3 percentage points more adherent than the entire study cohort (77.7% vs. 70.4%). People with self-reported severe sleep apnea were 78% adherent at the one-year mark, compared to 70.5% of those with self-reported moderate sleep apnea, and 65.2% of those with mild sleep apnea. “Sleep specialists, pulmonologists, and primary care physicians should heed these results and ensure that their younger, female, and more mildly diagnosed patients have the proper supports to stay on therapy,” said Adam B
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme